Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases
Patients with different autoimmune inflammatory diseases (AIID) on biological therapy are at risk of pneumococcal disease. Adults with inflammatory arthropathies, connective tissue diseases, psoriasis, or inflammatory bowel disease on biological therapy such as anti-TNFα, rituximab, tocilizumab, aba...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-02-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/9/3/203 |
| _version_ | 1797416843008278528 |
|---|---|
| author | Patricia Richi Jose Yuste Teresa Navío Laura González-Hombrado Marina Salido Israel Thuissard-Vasallo Ana Jiménez-Díaz Jesús Llorente Laura Cebrián Leticia Lojo Martina Steiner Tatiana Cobo María Dolores Martín Marta García-Castro Patricia Castro Santiago Muñoz-Fernández |
| author_facet | Patricia Richi Jose Yuste Teresa Navío Laura González-Hombrado Marina Salido Israel Thuissard-Vasallo Ana Jiménez-Díaz Jesús Llorente Laura Cebrián Leticia Lojo Martina Steiner Tatiana Cobo María Dolores Martín Marta García-Castro Patricia Castro Santiago Muñoz-Fernández |
| author_sort | Patricia Richi |
| collection | DOAJ |
| description | Patients with different autoimmune inflammatory diseases (AIID) on biological therapy are at risk of pneumococcal disease. Adults with inflammatory arthropathies, connective tissue diseases, psoriasis, or inflammatory bowel disease on biological therapy such as anti-TNFα, rituximab, tocilizumab, abatacept, or anakinra were included in this study. Patients completed a protocol combining the pneumococcal vaccines PCV13 and PPV23. Immune response against pneumococcal serotypes 1, 3, 7F, 14, 19A, and 19F were assessed evaluating functional antibodies by an opsonophagocytosis killing assay (OPKA). In this study, 182 patients with AIID completed the sequential vaccination protocol. Patients on etanercept tended to achieve OPKA titers against a larger number of serotypes than the rest of patients on other biological therapies, while adalimumab was associated to a lower number of serotypes with OPKA titers. Rituximab was not associated with a worse response when compared with the rest of biological agents. Not glucocorticoids, nor synthetic disease-modifying antirheumatic drugs, interfered with the immune response. OPKA titers against serotype 3 which is one of the most prevalent, was obtained in 44% of patients, increasing up to 58% in those on etanercept. Hence, almost 50% of patients on biological therapy achieved functional antibodies after the administration of a complete pneumococcal vaccination protocol. |
| first_indexed | 2024-03-09T06:10:01Z |
| format | Article |
| id | doaj.art-0b7b51666d9d401fae5073e96b3da8e0 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T06:10:01Z |
| publishDate | 2021-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-0b7b51666d9d401fae5073e96b3da8e02023-12-03T11:58:54ZengMDPI AGVaccines2076-393X2021-02-019320310.3390/vaccines9030203Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory DiseasesPatricia Richi0Jose Yuste1Teresa Navío2Laura González-Hombrado3Marina Salido4Israel Thuissard-Vasallo5Ana Jiménez-Díaz6Jesús Llorente7Laura Cebrián8Leticia Lojo9Martina Steiner10Tatiana Cobo11María Dolores Martín12Marta García-Castro13Patricia Castro14Santiago Muñoz-Fernández15Rheumatology Unit, Hospital Universitario Infanta Sofía San Sebastián de los Reyes, 28702 Madrid, SpainSpanish Pneumococcal Reference Laboratory, National Center for Microbiology, Instituto de Salud Carlos III, 28220 Madrid, SpainRheumatology Unit, Hospital Universitario Infanta Leonor, 28031 Madrid, SpainRheumatology Unit, Hospital del Tajo, Aranjuez, 28300 Madrid, SpainRheumatology Unit, Hospital Universitario Infanta Cristina, Parla, 28981 Madrid, SpainSchool of Doctoral Studies & Research, Universidad Europea, 28670 Madrid, SpainRheumatology Unit, Hospital Universitario Infanta Sofía San Sebastián de los Reyes, 28702 Madrid, SpainPharmacy Department, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, 28702 Madrid, SpainRheumatology Unit, Hospital Universitario Infanta Leonor, 28031 Madrid, SpainRheumatology Unit, Hospital Universitario Infanta Leonor, 28031 Madrid, SpainRheumatology Unit, Hospital Universitario Infanta Sofía San Sebastián de los Reyes, 28702 Madrid, SpainRheumatology Unit, Hospital Universitario Infanta Sofía San Sebastián de los Reyes, 28702 Madrid, SpainBR Salud Laboratories, Bacteriology Department, San Sebastián de los Reyes, 28702 Madrid, SpainRheumatology Unit, Hospital del Tajo, Aranjuez, 28300 Madrid, SpainRheumatology Unit, Hospital Universitario Infanta Cristina, Parla, 28981 Madrid, SpainRheumatology Unit, Hospital Universitario Infanta Sofía San Sebastián de los Reyes, 28702 Madrid, SpainPatients with different autoimmune inflammatory diseases (AIID) on biological therapy are at risk of pneumococcal disease. Adults with inflammatory arthropathies, connective tissue diseases, psoriasis, or inflammatory bowel disease on biological therapy such as anti-TNFα, rituximab, tocilizumab, abatacept, or anakinra were included in this study. Patients completed a protocol combining the pneumococcal vaccines PCV13 and PPV23. Immune response against pneumococcal serotypes 1, 3, 7F, 14, 19A, and 19F were assessed evaluating functional antibodies by an opsonophagocytosis killing assay (OPKA). In this study, 182 patients with AIID completed the sequential vaccination protocol. Patients on etanercept tended to achieve OPKA titers against a larger number of serotypes than the rest of patients on other biological therapies, while adalimumab was associated to a lower number of serotypes with OPKA titers. Rituximab was not associated with a worse response when compared with the rest of biological agents. Not glucocorticoids, nor synthetic disease-modifying antirheumatic drugs, interfered with the immune response. OPKA titers against serotype 3 which is one of the most prevalent, was obtained in 44% of patients, increasing up to 58% in those on etanercept. Hence, almost 50% of patients on biological therapy achieved functional antibodies after the administration of a complete pneumococcal vaccination protocol.https://www.mdpi.com/2076-393X/9/3/203PPV23PCV13OPKA titersinvasive pneumococcal diseasebiological therapyanti-TNFα |
| spellingShingle | Patricia Richi Jose Yuste Teresa Navío Laura González-Hombrado Marina Salido Israel Thuissard-Vasallo Ana Jiménez-Díaz Jesús Llorente Laura Cebrián Leticia Lojo Martina Steiner Tatiana Cobo María Dolores Martín Marta García-Castro Patricia Castro Santiago Muñoz-Fernández Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases Vaccines PPV23 PCV13 OPKA titers invasive pneumococcal disease biological therapy anti-TNFα |
| title | Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases |
| title_full | Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases |
| title_fullStr | Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases |
| title_full_unstemmed | Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases |
| title_short | Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases |
| title_sort | impact of biological therapies on the immune response after pneumococcal vaccination in patients with autoimmune inflammatory diseases |
| topic | PPV23 PCV13 OPKA titers invasive pneumococcal disease biological therapy anti-TNFα |
| url | https://www.mdpi.com/2076-393X/9/3/203 |
| work_keys_str_mv | AT patriciarichi impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases AT joseyuste impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases AT teresanavio impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases AT lauragonzalezhombrado impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases AT marinasalido impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases AT israelthuissardvasallo impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases AT anajimenezdiaz impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases AT jesusllorente impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases AT lauracebrian impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases AT leticialojo impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases AT martinasteiner impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases AT tatianacobo impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases AT mariadoloresmartin impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases AT martagarciacastro impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases AT patriciacastro impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases AT santiagomunozfernandez impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases |